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Background: CD4+CD25+ regulatory T cells (Tregs) play an important role in maintaining immunological tolerance
to self and foreign antigens. T cell receptors (TCR) reflect the composition and function of T cells. It is not
universally agreed that there is a relationship between CD4+CD25+ Treg frequency and the severity of
acute-on-chronic liver failure (ACLF). The repertoire of TCR beta chain variable (TCRBV) regions of peripheral
Tregs in ACLF patients is not well understood.
Methods: Human PBMCs were separated and sorted into CD4+CD25+ Treg subsets using density gradient
centrifugation and magnetic activated cell sorting (MACS). The CD4+CD25high Treg frequency in peripheral blood of
ACLF and chronic hepatitis B (CHB) patients was measured by flow cytometry. The molecular profiles of TCRBV
CDR3 were determined using gene melting spectral pattern (GMSP) analysis. TCRBV gene families were cloned and
sequenced when the GMSP profiles showed a single-peak.
Results: CD4+CD25high Treg prevalence in peripheral blood of ACLF patients is increased significantly compared to
healthy donors (HDs) (P< 0.01) and CHB patients (P< 0.01). The prevalence of CD4+CD25high Tregs in ACLF or CHB
patients is positively correlated with HBV DNA load. The TCRBV11, BV13.1, BV18, BV20 are the most prevalent TCRBV
in CD4+CD25+ Tregs in ACLF and CHB patients. In addition, the CDR3 motifs were relatively conserved in these four
TCRBV gene families.
Conclusions: The CD4+CD25high Tregs prevalence in peripheral blood is indicative of disease severity in ACLF or
CHB patients. The relatively conserved TCRBV20 CDR3 motif “TGTGHSPLH” and TCRBV11 CDR3 motif “VYNEQ” may
be used in helping diagnosis and treat patients with ACLF.Background
Hepatitis B virus (HBV) is responsible for chronic infec-
tion. Despite a reduction in new HBV infections since
the introduction of vaccination in the early 1990s, there
are approximately 350 million chronic HBV carriers
worldwide, and HBV remains an important cause of liver
disease in developed countries [1]. HBV infection can
lead to a spectrum of liver diseases, including chronic
asymptomatic HBV carrier (AsC), chronic hepatitis B
(CHB), liver cirrhosis (LC) and hepatocellular carcinoma
(HCC) or acute-on-chronic liver failure (ACLF) [2,3].* Correspondence: ljli@zju.edu.cn
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Commons Attribution License (http://creativec
reproduction in any medium, provided the orHBV-related ACLF is an acute decompensation of
chronic liver disease due to precipitating events such as
upper gastrointestinal (UGI) bleeding, ischemia, or add-
itional superimposed liver injury due to alcohol, hepato-
toxic drugs, surgical procedures, or reactivation of viral
hepatitis [4]. ACLF has a relatively high mortality and
liver transplantation serves as the most promising treat-
ment for ACLF [5-7]. However, a serious lack of livers
limits the utility of liver transplantation. Although the
role of T-cell immunity in ACLF pathogenesis is receiv-
ing more attention, it is not well understood.
Recent studies have shed light on CD4+CD25+ regula-
tory T cells (Tregs) that actively maintain immune toler-
ance to both self and non-self-antigens by suppressing
an aggressive T-cell response [8]. Studies indicate that
an increase of circulating CD4+ CD25+ Tregs ared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of HBV patients and healthy
controls
ACLF n=25 CHB n=30 HCs n= 30
Age (years) 43 ± 10 38 ± 7 36± 7
Gender (M/F) 16/9 21/9 18/12
ALT (IU/L) 327± 215 223 ± 124 18 ± 9
TBiL (μmol/L) 410.0 ± 150.2 133.2 ± 51.2 12.3 ± 3.7
HBV DNA(lgcps/mL) 5.3 ± 1.2 5.7 ± 1.6 ND
HBeAg (positive/negative) 12/13 18/12 ND
HBV genotype 15B, 10C 18B, 12C ND
These values expressed as mean ± SD, unless otherwise indicated.
Normal values: ALT, ≤ 40 IU/L; TBiL, ≤ 21 μmol/L.
ACLF, acute-on-chronic liver failure; ALT, alanine transaminase; CHB, chronic
hepatitis B; DNA, deoxyribonucleic acid; HBV, hepatitis B virus; HCs, healthy
controls; TBiL, Total bilirubin; ND, no detected.
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regulated HBV-specific T cells [9,10]. The occurrence of
ACLF often represents a complicated state of host im-
mune dysregulation, in which exacerbated innate
immune responses and aberrant adaptive immune
responses may play an important role in mediating hep-
atic inflammation and liver necrosis. However, it is still
controversial as to how the peripheral frequency of CD4
+CD25+ Treg changes in patients with HBV-related
ACLF [11,12].
The T cell receptor (TCR) repertoire can reflect the
function, status, and composition of T cell populations
in vivo. Characterization of the TCR repertoire of CD4
+CD25+ Treg subsets from hepatitis B patients may
clarify its role in ACLF pathogenesis. Furthermore,
understanding TCR expression during disease progres-
sion, including for infectious diseases, may aid diagnosis
and treatment [13]. In this study, we examined the fre-
quency of peripheral CD4+CD25+ Tregs from HBV-
infected ACLF patients, and the TCRBV CDR3 reper-
toire in Tregs from ALCF and CHB patients. A relation-
ship between Treg frequency and HBV DNA load in
ACLF or CHB patients was observed.
Materials and methods
Subjects
Patients with HBV-related ACLF (n = 25) and patients
with CHB (n = 30) were admitted to the Department of
Infectious Disease, the First Affiliated Hospital, College
of Medicine, Zhejiang University, between February and
June 2011. Healthy donors (n = 30) were selected as con-
trols and matched for sex ratio and age with the patient
groups. Written informed consent was obtained from all
subjects prior to enrollment. The study was conducted
according to the guidelines of the Declaration of Hel-
sinki. The Zhejiang University medical ethics committee
approved all procedures involving human subjects.
The diagnostic standards for patients with ACLF is set
by the Consensus Recommendation on ACLF issued by
the Asian Pacific Association for the Study of the Liver
(APASL) [14], and the Diagnostic and Treatment Guide-
lines for Liver Failure [15]. ACLF patients were categorized
as follows: (a) a history of chronic hepatitis or well-
compensated cirrhosis with the presence of serum
HBsAg ≥ 6 months; (b) recent development of severe
jaundice with total bilirubin ≥ 171 μmol/L plus increasing
international normalized ratio (INR) ≥ 1.5 or decreasing
prothrombin activity (PTA) ≤ 40%; and (c) recent devel-
opment of coagulopathy, obvious ascites, hepatic enceph-
alopathy, hepatorenal syndrome [16]. Patients with CHB
fulfilled the definitions described in detail elsewhere [11].
Patient characteristics at the time of the study are shown
in Table 1. Patients co-infected with human immunodefi-
ciency virus (HIV), hepatitis A virus (HAV), hepatitis Cvirus (HCV), hepatitis D virus (HDV), or hepatitis E virus
(HEV), were excluded. Patients treated with anti-viral or
immunomodulatory drugs within the previous 6 months,
or suffering from a complication of spontaneous bacterial
peritonitis (SBP) were excluded too. Peripheral venous
blood samples were obtained after liver disease was diag-
nosed. The anti-viral treatment was applied together with
conventional medical treatment, after the blood samples
were obtained. Among the ACLF patients, 14 cases
treated with entecavir (Bristol-Myers Squibb) 0.5 mg/d,
and the remaining 11 cases with lamivudine (GlaxoS-
mithKline) 100 mg/d.
Biochemical and serological markers and quantification of
HBV DNA
Biochemical tests of liver function examined serum ala-
nine amino transferase (ALT), aspartate amino transfer-
ase (AST), total bilirubin (TBiL), and creatinine (CREA)
using an automated biochemical analyzer (AEROSET,
Abbott, Chicago, IL, USA). Prothrombin activity (PTA)
and international normalized ratio (INR) were derived
from prothrombin time (PT) and determined using an
automated coagulation analyzer (Sysmex CA-500 Series,
Siemens, Deerfield, IL, USA). Qualitative assessment of
HBV markers (HBsAg/anti-HBs, HBeAg/anti-HBe, anti-
HBc) was determined using commercial enzyme im-
munoassay kits (LJ biology, Shanghai, China). Serum
HBV DNA load was quantified and HBV genotypes were
determined using commercial kits as described previ-
ously [17,18], with a minimal detection standard of 500
copies/mL.
Peripheral blood mononuclear cell (PBMCs) isolation and
flow cytometric analysis
PBMCs were isolated from 10 ml fresh EDTAK2 anti-
coagulant-treated blood using Ficoll-Paque (StemCell
Technologies Inc., Vancouver, Canada) density gradient
separation. To determine the frequency of the CD4
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bated with fluorochrome-conjugated antibodies (BD Bio-
science, Franklin Lakes, NJ, USA) to T cell surface
markers CD4 (FITC-conjugated anti-CD4 antibody) and
CD25 (PE-conjugated anti-CD25 antibody) at 4°Cfor
30 min. Red blood cells were lysed, stained, and fixed in
1% paraformaldehyde. Stained cells were washed twice
with sheath fluid, and the percentage of CD4+CD25+
Tregs in the total CD4+ lymphocyte population was ana-
lyzed using flow cytometry (Beckman Coulter Fc500
MPL, Coulter, Fullerton, USA), and isotype-matched
control antibodies.
Preparation of CD4+CD25+ regulatory T cells and flow
cytometric analysis
CD4+CD25+ Tregs were isolated from fresh PBMCs. Briefly,
CD4+ T cell subsets were negatively selected using a CD4+
T cell biotin-antibody cocktail and anti-biotin microbeads.
CD4+CD25+ T cells were further isolated from CD4+ T cells
using anti-CD25 antibody-coated magnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the man-
ufacturer’s instructions. The purity of CD4+CD25+ Tregs
was≥90% (data not shown), as determined by CD4/CD25
flow cytometric analysis using surface staining. For intracel-
lular staining, the purified of CD4+CD25+ Tregs were trea-
ted with Fix & Perm Reagent (Coulter) after labelling with
surface antibodies, and then incubated with anti-Foxp3
(eBioscience, San Diego, CA, USA), and the following steps
as described above. The data were analyzed using MXP
software (Coulter). The CD4+CD25+ Tregs were followed
total RNA extracted, when the percentages of intracellu-
lar FoxP3-positive T cells in CD4+ T-cell subsets from
ACLF or CHB patients were about 80%. In addition, the
average frequency of CD127low expressed on these CD4
+CD25+ Tregs is approximately 80% (data no shown).
RNA extraction and cDNA synthesis
Total RNA was extracted from CD4+CD25+ Tregs using
TRIzolW (Invitrogen, Carlsbad, California, USA) or RNea-
syW Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. RNA was quantified using a
NanoDropW ND-2000 spectrophotometer (Thermo Fisher
Scientific, Wilmington, Delaware, USA), and integrity was
checked electrophoretically (28S and 18S). Total RNA was
immediately reverse transcribed to cDNA using the Rever-
tAid First Strand cDNA Synthesis Kit (MBI, Fermentas,
EU) per manufacturer’s instructions. Briefly, ~1-5 μg total
RNA was reverse transcribed with OligodT18 in a 20 μL re-
action volume and stored at −20°C.
GMSP assay of TCRBV in CD4+CD25+ tregs to identify
skewed TCRBV repertoire
The GoTaqW qPCR Master Mix (with Rox™ dye) was
used as PCR kit (Promega, Madison, WI, USA). Amaster mix of 20 μl for each of the 28 reactions contain-
ing 0.5 μM reverse primer TCRBC, and 50~ 150 ng
template cDNA was prepared. For family specific
TCRBV amplification, the corresponding forward primer
(TCRBV1~ 24) was added to a final concentration of
0.5 μM. The real time PCR reaction parameters were as
follows: 2 min at 95°Cto activate the GoTaq enzyme, fol-
lowed by 45 cycles at 95°Cfor 15 s, 56.5°Cfor 20 s, and
72°Cfor 25 s with a final extension at 72°Cfor 8 min. The
melting curve for 24 TCRBV gene families was
determined by plotting the first negative derivative of
the decrease in fluorescence signal as a function of
temperature (−dF/dT) versus temperature (Tm), gener-
ating gene melting spectral patterns (GMSPs) as previ-
ously reported [19].
A skewed clonal expansion was determined using the
GMSP profile of each TCRBV family using Opticon
Monitor 3.0 and the MJ Opticon 2 DNA engine
(Bio-Rad, Hercules, CA, USA). GMSP profiles were in
one of two categories: 1) “Oligoclonal expansion”, or 2)
“Monoclonal”, as defined previously [20].
Cloning and sequencing
If a TCRBV gene family demonstrated a monoclonal
GMSP profile (single peak), the sample was selected for
cloning and sequencing to determine the degree of
homogeneity within the CDR3 region. Briefly, PCR pro-
ducts were reamplified using GoTaq DNA polymerase
(Promega, Madison, WI, USA) and touchdown PCR.
The parameters were: pre-incubation at 95°Cfor 2 min,
95°Cfor 30 s, 60°Cfor 40 s, 72°Cfor 45 s, for 8 cycles with
annealing temperature decreasing 0.5°Cper cycle, and
95°Cfor 45 s, 56°Cfor 45 s, 72°Cfor 50 s, for 27 cycles.
The cycling was followed by a terminal elongation step
at 72°Cfor 8 min.
Purified PCR products were ligated into pGEMT-T
using the pGEM-3Z Cloning Kit (Promega, USA)
according to the manufacturer’s instructions. Cloning
details have been described previously [21]. The plasmid
DNA was sequenced using an ABI3730 DNA Sequencer
(Applied Biosystems, Foster City, USA). The resulting
sequences were compared against a standard TCRBV
gene database (http://www.imgt.org).
Statistical analysis
All data were analyzed using SPSS software version 16.0
(SPSS Inc., Chicago, USA). TCRBV families were ana-
lyzed using the Kruskal–Wallis H test or Mann–Whitney
nonparametric U test. Differences in data between two
families were examined using a χ2-test or Student’s t-test.
Spearman correlation analysis was performed to deter-
mine differences in CD4+CD25+ Treg frequency and
other parameters (serum ALT, TBiL, and CREA levels),
with a P < 0.05 considered statistically significant.
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ACLF patients with increased frequency of CD4+CD25+
Tregs
The CD4+CD25high subset has been counted to
represent the CD4+CD25+ Treg frequency in HBV and
HIV-infected patients [22,23]. In the study, we thus
determined the frequency of CD4+CD25+ Treg in total
CD4+ by measuring CD4+CD25high (fluorescence in-
tensity of CD25 >50) population. Our results indicate
that patients with HBV related-ACLF had a signifi-
cantly higher frequency of peripheral CD4+CD25high
Tregs (mean, 6.24%) than CHB patients (mean, 4.16%,
P < 0.01) and healthy controls (mean, 2.09%, P < 0.01).
Moreover, there was a significant difference in the
circulating proportion of CD4+CD25high Tregs bet-
ween CHB patients and healthy controls (P < 0.01)
(Figure 1A). A representative flow plot demonstrating
the frequency CD4+CD25+ Tregs in peripheral blood
from ACLF patients, CHB patients and healthy con-
trols is shown in Figure 1B.Figure 1 Percentages of CD4+CD25+ Tregs within total CD4+ T popula
controls. The CD4+CD25+ Tregs are gated from a mononuclear cell subset
peripheral blood from three groups (ACLF, CHB patients, and healthy contr
black solid line is the median frequency of Tregs. Vertical lines represent th
calculated using the Kruskal–Wallis H nonparametric test. (B) Representative
CD4 and CD25. CD4+CD25+ Tregs were separated into CD4+CD25high, CD4
obtained using isotypic control antibody.Relationship between Treg frequency and HBV DNA load
There was a positive correlation between CD4+CD25+
Treg frequency in peripheral blood from ACLF patients
and serum HBV DNA load (r = 0.432, P= 0.031)
(Figure 2A). A similar positive correlation was also
observed in CHB patients (r = 0.378, P= 0.039)
(Figure 2B). Furthermore, in ACLF patients and CHB
patients, there was no correlation between circulating
CD4+CD25+ Tregs and serum ALT, TBiL, and CREA
levels (data not shown).
Tregs have a skewed TCRBV repertoire
We compared the Tregs TCRBV CDR3 profiles from
ACLF and CHB patients to those of healthy controls.
ACLF and CHB patients contained a greater number of
skewed-clonally derived TCRBV families relative to con-
trols. Although ACLF patients displayed a lower average
ratio of skewed TCRBV families than CHB patients, it
was not significantly different (P > 0.05) (Table 2). The
number of single and biased-peaks for 24 TCRBVtion in peripheral blood in ACLF, CHB patients, and healthy
of peripheral whole blood. (A) Frequencies of CD4+CD25high Tregs in
ols, HC). Data are expressed as box plots, in which the middle of the
e 10th and 90th percentiles. The p values of multiple comparisons were
scatter plots are obtained by flow cytometry using antibodies against
+CD25low subsets, defined by the fluorescence intensity of CD25 (> 50)
Figure 2 Correlation between CD4+CD25+ Treg frequency and common logarithm (log10) of HBV DNA load in patients with ACLF or
CHB.
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ACLF and CHB patients. Four TCRBV gene families
(BV11, BV13.1, BV18, BV20) were more prevalent than
other TCRBV members (Table 2). A representative
GMSP profile of a monoclonal TCRBV expressed in
CD4+CD25+ Tregs from ACLF and CHB patients is
shown in Figure 3.
TCRBV CDR3 amino acid motifs in Tregs
The total number of TCRBV gene families with single
peak shape (GMSP) in ACLF or CHB patients is 35 and
41 respectively. The TCRBV CDR3 gene families were
cloned, sequenced, and translated to corresponding
amino acid sequences. Representative amino acid
sequences of TCRBV CDR3 from ACLF or CHB patients
are shown in Table 3. We found that several different
ACLF patients exhibited monoclonal expansion of rela-
tively conserved TCRBV CDR3, such as BV20
(TGTGHSPLH with BJ1.6), BV18 (RTGDTEA with
BJ1.1), BV13.1 (EVRTAFYEQ with BJ2.7) and BV11(VYNEQ with BJ2.1). CHB patients also expressed rela-
tively conserved TCRBV CDR3, such as BV20
(TGTGHSPLH with BJ1.6), BV18 (DDQETQ with
BJ2.5), BV13.1 (YSGQGIDGY with BJ1.2) and BV11
(SSGGVDTQ with BJ2.3). Four TCRBV gene families
(BV11, BV13.1, BV18, BV20) were more prevalent than
the other TCRBV families.
Discussion
CD4+CD25+ Tregs are important immune regulatory
cells. Their primary role is regulating the immune re-
sponse through immune suppression by inhibiting the
immune system response to both self and foreign anti-
gens. Treg cells inhibit excessive pathological damage by
inhibiting HBV-specific CD8 + T cell activation, which
may aid persistent virus infection [8]. In addition to inhi-
biting CD4 +/CD8 + T cells in vivo, Treg cells also inhibit
dendritic cell (DCs) activation and cytokine secretion,
preventing an excessive inflammatory response. We
show here that increased prevalence of CD4+CD25+
Table 2 Frequency of skewed TCRBV families in CD4










1 3 5 0
2 4 3 1
3 3 5 1
4 5 6 2
5.1 6 (26.1) 3 2
5.2 2 6 1
6 2 5 2
7 5 6 1
8 3 3 2
9 3 2 3
10 5 3 1
11 9 (39.1) 9 (33.3) 2
12 6 (26.1) 6 1
13.1 7 (30.1) 8 (29.6) 2
13.2 3 6 2
14 3 2 1
15 4 8 (29.6) 1
16 3 5 2
17 5 7 (25.9) 1
18 8 (34.8) 9 (33.3) 2
19 2 2 0
20 10 (43.5) 11 (40.7) 2
21 1 5 1
22 3 7 (25.9) 1
23 5 5 0
24 3 5 2
Total no. of skewed
Vβ (average
ratio for a case)
113 (4.91) c, d 142 (5.26) c, d 36 (2.12) c
No. of patients examined
with normal pattern e
(ratio,%)




aThe number of TCRBV gene families showing skewed-clone expansion
(oligoclonal or monoclonal) is summarized in patients with ALCF, CHB and HCs.
bThe number of samples showing a skewed-clone expansion in total detected
samples (percentages of each TCRBV skewed-clone expansion). Samples with
normal GMSP are excluded in the percentage calculation.
cThe average skewed expansion rate of TCRBV gene families was higher in
CD4+CD25+ Treg from patients with ACLF or CHB than that of HC group
(P< 0.01 by χ2 test).
dThere was no significant difference between the two groups (P > 0.05 by χ2
test). Samples with normal GMSP are excluded in the average ratio calculation
eNormal pattern (GMSP) means that there is no monoclonal or oligoclonal
pattern in any TCRBV families in a patient.
fThe incidence of the normal GMSP was significantly lower in CD4+CD25+ Treg
from patients with ACLF or CHB than that of HC group (P< 0.01 by χ2 test).
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cation and disease severity in HBV patients.
Several studies have tried to characterize the role of
peripheral CD4+CD25+ Tregs in chronic HBV infection.
However, the relationship between Tregs and ACLF
pathogenesis is not well established, and in fact, the con-
clusions from two earlier studies were not consistent
[11,12]. Our data are very similar to the findings
observed by Xu et al. Those results support the notion
that in HBV infected ACLF patients, up-regulation of
CD4+CD25+ Tregs might play a critical role in suppres-
sing immune responses, contributing to chronic HBV in-
fection. In addition, the prevalence of circulating CD4
+CD25+ Tregs is increased in CHB patients as described
by Peng et al. [9]. Conversely, Wang et al. found a sub-
stantial decrease in peripheral CD4+CD25+CD127low
Tregs in ACLF patients. The discrepancies between
these studies may be attributed largely to differences in
techniques, reagents, and blood samples, as well as the
molecular markers used for identifying Tregs.
HBV replication may play an important role in pre-
cipitating liver failure in patients with chronic HBV in-
fection. Our results demonstrate a positive correlation
between peripheral CD4+CD25+ Tregs and HBV DNA
load in patients with HBV-related ACLF or CHB. Inter-
estingly, adefovir treatment induced reduction of HBV
DNA, a decrease in Tregs, and an increase in HBV-
specific CD4+ and CD8+ T cell proliferation and IFN-
gamma production [24]. These observations support the
notion that an increase in CD4+CD25+ Treg may reduce
HBV specific immune responses, leading to ongoing
HBV replication and chronic infection.
T cells are quite heterogeneous due to the large reper-
toire of TCRs, which can serve as a “molecular finger-
print” of T cell populations [25]. Each T cell clone
expresses a unique TCR that recognizes antigen-derived
peptide bound to a major histocompatibility complex
(MHC). The CDR3 region is the key determinant of T
cell antigen specificity and mediates T cell diversity
[26,27]. Therefore, analysis of the CDR3 profile reflects
changes in the T cell population stimulated by a specific
antigen [28,29]. In the current study, we found four
TCRBV gene families (BV11, BV13.1, BV18, BV20) to be
more prevalent than other members in CD4+CD25+
Tregs from ACLF and CHB patients, which suggests
these four families may be indicative of patients with
chronic HBV infection. Moreover, TCRBV5.1 is present
at a higher frequency in ACLF patients than in CHB
patients, which may indicate the TCRBV5.1 family may
have a potential role in ACLF pathogenesis, although,
this underlying mechanism requires further exploration.
Immune suppression plays an important role in
the treatment of chronic hepatitis B. Inhibiting Treg
proliferation and differentiation, blocking regulatory
Figure 3 Representative GMSP with a single-peak (monoclonal expansion) of TCRBV families in CD4+CD25+ Treg from ACLF and CHB
patients. The TCRBV gene families in the top graphs corresponding to P43 (BV20), P70 (BV20), P51 (BV18), P46 (BV13.1), P25 (BV12), and P47
(BV11). The TCRBVs shown in the bottom graphs correspond to P20 (BV22), P17 (BV20), P57 (BV18), P45 (BV17), P17 (BV15), and P44 (BV13.1). The
correspond amino acid sequences are shown in Table 3. The melting temperature is on the x-axis of each plot. The negative first derivative of the
decrease in fluorescence as a function of temperature (−dF/dT) is shown on the y-axis.
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epitope-specific CTL immune responses, are all potential
new treatment strategies for hepatitis B [30,31]. AtTable 3 Representative amino acid sequences of monoclonal
ACLF or CHB
Patientsa Vbeta CD
43 (ACLF) BV20 SGFYLCAWS TGTGH
70 (ACLF) BV20 SGFYLCAWS TGTGH
67 (ACLF) BV20 SGFYLCAWS TGTGH
6 (ACLF) BV20 SGFYLCAWR ISHT
16 (ACLF) BV20 SGFYLCAWS GGSN
51 (ACLF) BV18 SAAYFCASS RTGD
46 (ACLF) BV13.1 SVYFCASS EVRTA
25 (ACLF) BV12 SVYFCAIS DGQV
47 (ACLF) BV11 SQYLCATG VYN
51 (ACLF) BV11 SQYLCATG VYN
10 (ACLF) BV5.1 SALYLCASS LEQLTR
20 (CHB) BV22 SAMYFCASK GSREGL
17 (CHB) BV20 SGFYLCAWS TGTG
57 (CHB) BV18 SAAYFCASS DDQ
45 (CHB) BV17 TAFYLCASS IVNGG
17 (CHB) BV15 TALYFCATS DPASGR
44 (CHB) BV13.1 SVYFCASS YSGQG
3 (CHB) BV11 SQYLCATT SSGGV
When the GMSP profile of a TCRBV family displayed a single peak, the correspondin
amino acid sequences of the max rate of TCRBV families are shown. aThe clinical typresent, blocking T cell function using monoclonal anti-
bodies against the TCR [32], and TCR gene transfer have
been developed as a reliable method to generate largeTCRBV families in CD4+CD25+ Tregs from patients with
R3 BJ Ratio
SPLH FGNGTRLTVTED 1.6 17/21
SPLH FGNGTRLTVTED 1.6 19/23
SPLH FGNGTRLTVTED 1.6 13/22
GEL LFGEGSRLTVLED 2.2 16/22
QPQ HFGDGTRLSILEDL 1.5 13/20
TEA FFGQGTRLTVVED 1.1 16/21
FYEQ YFGPGTRLTVTED 2.7 14/21
VEQ YFGPGTRLTVTED 2.7 15/22
EQ FFGPGTRLTVLED 2.1 20/20
EQ FFGPGTRLTVLED 2.1 20/20
ANKQ NFGPGTRLTVLED 2.3 17/23
VVNEQ FFGPGTRLTVLE 2.1 18/22
HSPL HFGNGTRLTVTED 1.6 21/23
ETQ YFGPGTRLLVLED 2.5 21/21
QPQ HFGDGTRLSILED 1.5 21/22
TNEQ FFGPGTRLTVLED 2.1 15/22
IDGY TFGSGTRLTVVED 1.2 16/22
DTQ YFGPGTRLTVLED 2.3 21/23
g PCR products re-amplified and the CDR3 were sequenced after cloning. The
pes of patients were indicated in brackets.
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and functional avidity. These results provide promise for
clinical application [33-37].
In the current study, we found that motifs of monoclo-
nal populations expressing TCRBV11, BV13.1, BV18,
and BV20 in CD4+CD25+ Tregs from ACLF patients are
different from that in CHB patients. It is not clear, how-
ever, if or how the emergence of the TCRBV families in-
fluence the course of ACLF. In a follow-up study, we
observed an interesting phenomenon, wherein the
TCRBV in CD4+CD25+ Tregs from ACLF patients
expressed TCRBV20 with the CDR3 sequence
“TGTGHSPLH”. Their short-term response to treatment
was better than that for ACLF patients with the TCRBV
CDR3 “ISHTGEL” or “GGSNQPQ” motifs. Moreover,
we found the CDR3 “TGTGHSPLH” motif expressed
only in the CHB patients whose condition was not as
serious. This suggests that “TGTGHSPLH” may be a
short-term prognostic biomarker for ACLF with anti-
viral treatment, although this requires further validation.
The TCRBV11 family prefers “VYNEQ” as a CDR3 motif
in ACLF patients, but expressed “SSGGVDTQ” in CHB
patients. This is partly consistent with our previous re-
port showing “AGEL” is the preferred motif in CHB
patients whose short-term outcomes are better than
CHB patients expressing the “VYNEQ” motif [20].
Therefore, conserved TCRBV gene families may help
produce antibody specific to TCRBV motifs, inhibiting
the corresponding CD4+CD25+ Tregs and aiding hepa-
titis B treatment. Moreover, production of antigen-
specific T cells using TCR gene transfer is a promising
idea for the treatment of liver disease [38], with reports
noting that CD8(+)CD45RC(low) Tregs are a potential
cell-based treatment [39]. Examining CD4+CD25+ Treg
TCR diversity may further our understanding of periph-
eral tolerance mechanisms and the role peripheral Tregs,
and how this applies to hepatitis B patients [40].
In the current study, because the volume of blood
samples was limited, the FoxP3 mRNA expression in
CD4+CD25+ Tregs was not confirmed. Another hurdle
is that CD4+CD25high Tregs were not isolated using a
cell sorter, and directly used for GMSP assay. But Peng
et al. described that CD4+CD25+ Tregs could represent
CD4+CD25high Tregs, when the CD4+ T cells including
high FoxP3-positive T cells content determined by flow
cytometry analysis [9].
Conclusions
Patients with HBV-related ACLF exhibited an increase in
circulating CD4+CD25+ Tregs, which was correlated with
HBV-related liver failure. An increase in peripheral Treg
has been associated with more severe liver disease in
hepatitis B patients. The relatively conserved TCRBV20
CDR3 “TGTGHSPLH” and TCRBV11 CDR3 “VYNEQ”motif could be used in predicting the health status of
patients with ACLF or CHB, and may help in the devel-
opment of transduction TCR gene therapy for ACLF
patients.
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